MarketCap
Facebook
X
Telegram
Regulus Therapeutics Market Cap | RGLS
As of November 07, 2026 Regulus Therapeutics has a market cap of $ 155 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Regulus Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 52.7 M | 16.9 M | 2.74 M | 48.6 M | 18.6 M | 8.2 M | 94.8 M | 68.7 M | 297 M | 844 M | 355 M | 49.1 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 844 M | 2.74 M | 155 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Jaguar Health
JAGX
|
956 K | $ 0.4 | -2.16 % | $ 933 K |  USA |
 |
Arvinas
ARVN
|
869 M | $ 6.41 | -2.14 % | $ 454 M | USA |
 |
Cerus Corporation
CERS
|
496 M | $ 2.03 | -4.93 % | $ 387 M | USA |
 |
Beam Therapeutics
BEAM
|
3.2 B | $ 26.43 | 2.15 % | $ 2.61 B | USA |
 |
Fortress Biotech
FBIO
|
77.8 M | $ 1.86 | 0.82 % | $ 51.9 M | USA |
 |
Inhibrx
INBX
|
1.75 B | $ 84.71 | 5.52 % | $ 3.99 B | USA |
 |
Entera Bio Ltd.
ENTX
|
89.6 M | $ 3.16 | 5.69 % | $ 146 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
521 M | - | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
6.91 B | $ 23.43 | 3.95 % | $ 8.64 B | USA |
 |
CytomX Therapeutics
CTMX
|
931 M | $ 2.19 | 2.1 % | $ 302 M | USA |
 |
Krystal Biotech
KRYS
|
8.46 B | $ 300.7 | 0.15 % | $ 8.7 B | USA |
 |
Kura Oncology
KURA
|
735 M | $ 7.15 | 5.15 % | $ 627 M | USA |
 |
Inhibikase Therapeutics
IKT
|
160 M | $ 1.5 | 4.17 % | $ 147 M | USA |
 |
Heron Therapeutics
HRTX
|
198 M | $ 0.29 | 2.25 % | $ 48.3 M | USA |
 |
Inovio Pharmaceuticals
INO
|
98.5 M | $ 1.22 | -16.21 % | $ 57.2 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
318 M | $ 10.56 | 8.5 % | $ 834 M | USA |
 |
Aytu BioScience
AYTU
|
27.5 M | $ 1.82 | 0.55 % | $ 22.4 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
32.8 M | - | -5.76 % | $ 99.8 M | USA |
 |
Innoviva
INVA
|
1.62 B | $ 19.09 | -0.78 % | $ 1.29 B | USA |
 |
BioCardia
BCDA
|
8.07 M | $ 0.86 | -3.12 % | $ 5.73 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
196 M | - | 0.11 % | $ 419 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
29.4 B | $ 2.44 | 9.91 % | $ 15.6 B |  Australia |
 |
Shineco, Inc.
TYHT
|
13.2 M | - | -3.90 % | $ 97.2 M |  China |
 |
Millendo Therapeutics, Inc.
MLND
|
2.5 M | - | -5.36 % | $ 20.2 M | USA |
 |
Certara
CERT
|
1.08 B | $ 12.12 | -0.53 % | $ 1.94 B | USA |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.33 | -2.68 % | $ 11.9 M | USA |
 |
Intec Pharma Ltd
NTEC
|
16.1 M | - | -12.45 % | $ 17.7 M | Israel |
 |
Oramed Pharmaceuticals
ORMP
|
137 M | $ 3.86 | -0.77 % | $ 160 M | Israel |
 |
Anika Therapeutics
ANIK
|
214 M | $ 14.56 | -24.68 % | $ 209 M | USA |
 |
Aprea Therapeutics
APRE
|
4.97 M | $ 0.53 | 6.6 % | $ 3.47 M | USA |
 |
Galectin Therapeutics
GALT
|
178 M | $ 3.13 | 4.86 % | $ 200 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 72.79 | 1.62 % | $ 7.56 B | USA |
 |
Progenity, Inc.
PROG
|
339 M | - | -3.47 % | $ 164 M | USA |
 |
Genprex
GNPX
|
1.65 M | $ 2.09 | -0.48 % | $ 1.95 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
151 M | - | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
126 M | $ 1.43 | 2.14 % | $ 128 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
538 K | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 56.03 | -0.16 % | $ 10.7 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
2.74 M | $ 1.15 | -0.86 % | $ 6.3 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
259 K | $ 10.99 | 9.03 % | $ 234 K | USA |
 |
Milestone Pharmaceuticals
MIST
|
144 M | $ 0.76 | 9.73 % | $ 80.7 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
3.28 B | $ 93.79 | 6.17 % | $ 6.96 B | USA |
 |
Lipocine
LPCN
|
17.9 M | $ 1.58 | 3.27 % | $ 8.61 M | USA |
 |
Seres Therapeutics
MCRB
|
62 M | $ 1.97 | -5.74 % | $ 17.5 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
9.89 B | $ 399.41 | -0.17 % | $ 8.96 B | USA |
 |
CEL-SCI Corporation
CVM
|
19.9 M | $ 1.44 | 6.67 % | $ 11.5 M | USA |
 |
Inventiva S.A.
IVA
|
184 M | $ 3.8 | 4.68 % | $ 227 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
651 M | $ 9.0 | 5.73 % | $ 724 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
4.14 M | $ 1.93 | 4.89 % | $ 2.53 M | USA |
 |
Eton Pharmaceuticals
ETON
|
559 M | $ 56.44 | 19.7 % | $ 1.52 B | USA |